Christopher Young - Pacira BioSciences, Chief Officer
| PCRX Stock | USD 17.38 0.35 2.06% |
Executive
Christopher Young is Chief Officer of Pacira BioSciences,
| Age | 52 |
| Address | 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 |
| Phone | 813 553 6680 |
| Web | https://www.pacira.com |
Christopher Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Young against Pacira BioSciences, stock is an integral part of due diligence when investing in Pacira BioSciences,. Christopher Young insider activity provides valuable insight into whether Pacira BioSciences, is net buyers or sellers over its current business cycle. Note, Pacira BioSciences, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pacira BioSciences,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Young over three weeks ago Disposition of 88219 shares by Christopher Young of Entravision Communications at 4.21 subject to Rule 16b-3 | ||
Christopher Young over three months ago Acquisition by Christopher Young of 1433 shares of MBIA at 7.16 subject to Rule 16b-3 | ||
Christopher Young over six months ago Acquisition by Christopher Young of 6527 shares of MBIA subject to Rule 16b-3 | ||
Christopher Young over six months ago Acquisition by Christopher Young of 1433 shares of MBIA subject to Rule 16b-3 |
Pacira BioSciences, Management Efficiency
The company has return on total asset (ROA) of 0.0417 % which means that it generated a profit of $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1148) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| SANJAY SHARMA | Dr Reddys Laboratories | 52 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Kumar Singh | Dr Reddys Laboratories | 74 | |
| Yiling Cui | HUTCHMED DRC | N/A | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Hong Chen | HUTCHMED DRC | 54 | |
| YUGANDHAR PUVVALA | Dr Reddys Laboratories | 48 | |
| Iain Brown | Alkermes Plc | 55 | |
| Suresh MD | Intracellular Th | 55 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Kin MBA | HUTCHMED DRC | 47 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Willie MD | Intracellular Th | N/A | |
| Declan OConnor | Alkermes Plc | N/A | |
| Sushrut Kulkarni | Dr Reddys Laboratories | 54 | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Larry Miller | Phibro Animal Health | 60 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0417 |
Pacira BioSciences, Leadership Team
Elected by the shareholders, the Pacira BioSciences,'s board of directors comprises two types of representatives: Pacira BioSciences, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pacira. The board's role is to monitor Pacira BioSciences,'s management team and ensure that shareholders' interests are well served. Pacira BioSciences,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pacira BioSciences,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Kahr, Vice Resources | ||
| Daryl Gaugler, Chief Officer | ||
| Charles Laranjeira, Chief Technical Officer | ||
| Christopher Young, Chief Officer | ||
| Shawn Cross, Chief Officer | ||
| DO Ellis, Chief Officer | ||
| III CPA, Chief Officer | ||
| Max Reinhardt, Pres World | ||
| Dennis McLoughlin, Chief Commercial Officer | ||
| David Stack, Chairman and CEO | ||
| Kristen JD, Chief Secretary | ||
| Roy MD, Chief Officer | ||
| Susan Mesco, IR Contact Officer | ||
| Jonathan MD, Chief Officer | ||
| Lauren Riker, Principal Finance | ||
| Frank Lee, CEO Director | ||
| Esq III, Chief Officer |
Pacira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pacira BioSciences, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0417 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 963.09 M | ||||
| Shares Outstanding | 46.17 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 5.46 M | ||||
| Price To Earning | 14.34 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.